Drugs Made In America Acquisition II Corp.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Drugs Made In America Acquisition II
Blank Checks, SIC 6770
Drugs Made In America Acquisition II Corp. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses. The company conducts no commercial operations and generates no revenue, operating solely as a shell company. Its business strategy focuses on acquiring operating entities in the pharmaceutical sector, specifically targeting businesses capable of advancing the domestic manufacturing of active pharmaceutical ingredients and critical finished generic drugs to enhance supply chain resilience.
Because the company has not commenced operations, it has no commercial presence, operational facilities, or physical retail footprint, holding nominal assets consisting almost entirely of cash. The company is incorporated as an exempted entity in the Cayman Islands and maintains its principal executive offices in New York, New York.
Summary of the business section of Drugs Made In America Acquisition II's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Drugs Made In America Acquisition II Corp.
- Founded
- 2024
- Headquarters
- New York, NY
- Address
- 420 Lexington Avenue, Suite 1402 10170
- Phone
- (954) 870-3104
- Industry
- Blank Checks
- Fiscal year ends
- December 31
- Auditor
- MaloneBailey, LLP, Houston, Texas
Stock & identifiers
- Ticker
- DMII
- Other tickers
- DMIIR, DMIIU
- Exchange
- Nasdaq
- IPO date
- Sep 25, 2025
- Shares outstanding
- 64M, Aug 14, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2040475
- CUSIP
- G2851K104
- ISIN
- USG2851K1046
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lynn Stockwell | CEO and Exe. Chair of Board, Director | 14,675,000 |
| Glenn C. Worman | CFO | 100,000 |
| Catherine Do | Director | 100,000 |
| Myron W. Shulgan | Director | 100,000 |
| Sridhar G. Prasad | Director | 100,000 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 1, 2026 | Late filing | Notification of late filing |
| Nov 17, 2025 | Late filing | Notification of late filing |
| Sep 25, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 24, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |